Search results | amgen


Partnering Agreements with Amgen

This report provides all the information you require to better understand Amgen and its partnering interests and activities over the past seven years.


Onyx Pharmaceuticals: Oncology specialists and a subsidiary of Amgen

Onyx Pharmaceuticals is a biotechnology company based in San Francisco developing therapies for the treatment of people living with cancer.


Amgen is a top biotechnology company based in Thousand Oaks, CA, USA

Dealtalk: Amgen said to push for lower Onyx price amid data dispute

Amgen is pushing to pay less than the $130 a share it offered this month for Onyx Pharmaceuticals after failing to obtain requested clinical trial data, according to dealtalk.

Dealtalk: Amgen, Onyx huddle on $9.5bn deal as other bidders fall away

In dealtalk, Amgen is closing in on a deal for Onyx Pharmaceuticals.

Dealtalk: Amgen Said to Boost Onyx Pharmaceuticals Bid to $130 a Share

Amgen, the drugmaker in pursuit of Onyx Pharmaceuticals, boosted its offer for the company to $130 a share, according to dealtalk.

Dealtalk: Onyx Seeks Suitors After Rejecting $120-a-Share Amgen Bid

Onyx Pharmaceuticals, the maker of the cancer drug Nexavar, said it is in contact with other possible acquirers after rejecting an unsolicited $120-a-share cash takeover bid from Amgen.

Dealtalk: Amgen and Pfizer interested in buying Biocad

Biocad, a Russian biotechnology company that’s trying to copy some of the world’s top-selling cancer medicines, is seeking a buyer, said two individuals in dealtalk.

Partnering with Amgen: Embracing the best ideas in science

Amgen is a top biopharma company active in partnering, licensing and M&A in human therapeutics with a focus on biotechnology

Amgen: Partnering activity 2005-2013

Amgen announced over 90 partnering / licensing deals since 2005, with 15 deals in 2012 alone

Amgen M&A deals and alliances 2005-2013

Amgen has announced over 11 M&A deals since 2005, with the lead deals being the acquisition of decode Genetics, MN Pharmaceuticals, KAI Pharmaceuticals, Micromet and Biovex


Sorry, your search returned no results.


Amgen and MD Anderson in bispecific T cell engager (BiTE) antibody pact

Amgen and The University of Texas MD Anderson Cancer Center announced a research collaborative agreement focusing on Amgen’s bispecific T cell engager (BiTE) antibody constructs

Amgen and Kite Pharma collaborate in CAR T cell immunotherapies

Amgen and Kite Pharma have entered into a strategic research collaboration and license agreement to develop and commercialize the next generation of novel Chimeric Antigen Receptor (CAR) T cell immunotherapies

Amgen biopharma partners for supporting startups

Amgen and LabCentral biopharma partners: announced an agreement in which Amgen has become a LabCentral platinum sponsor.

Merck forms pharma partnering with Amgen, Pfizer and Incyte

Merck  has signed three separate pharma partnering clinical collaboration agreements, through subsidiaries, with Amgen Inc., Incyte Corporation and Pfizer Inc. to evaluate novel combination regimens with MK-3475, Merck’s investigational anti-PD-1 immunotherapy.

Pharma deal between Illumina and Amgen

Illumina has entered into an pharma deal agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab).

Amgen signs a pharma licensing agreement with Carmot

Carmot Therapeutics has entered into a collaboration and pharma license agreement with Amgen.

Amgen biopharma partners with Roche for neutropenia drugs

Amgen biopharma partners by acquiring Roche’s rights to the neutropenia drugs filgrastim and pegfilgrastim, effective January 1, 2014

KineMed biopharma partners with Amgen for kinetic biomarkers

KineMed biopharma partners with Amgen, a big pharma company, to apply KineMed’s mass spectrometric Dynamic Proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases

Amgen proposes biotech business development

Amgen, a big pharma, and ShanghaiTech University announced the two organizations have entered into a memorandum of understanding to form a biotech business development  partnership for the advancement of biopharmaceutical discovery and translational research in China

Amgen in M&A deals with Onyx Pharmaceuticals for $10.4 billion acquisition

Amgen agreed to M&A deals for the acquisition of Onyx Pharmaceuticals for about $10.4 billion in cash to gain access to the company’s three anticancer treatments.